Ying Zhu
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (21)
Year:
2026
Single-cell proteomic (scProteomic) measurements of peripheral blood mononuclear cells (PBMCs) are of considerable value in human health, given their involvement in the maintenance of healthy and diseased states. However, the high heterogeneity and relatively small size of immune cell types demand maximal throughput and sensitivity in proteomic measurements that have yet to be fully realized. Here, we describe an approach that addresses sensitivity and throughput through the implementation of Real-Time spectral Library Searching (RTLS), TMTpro 32-plex labelling, an updated nested-nanodroplet processing in One pot for Trace Samples (N2), and a dual-column liquid chromatography system. By prioritizing tandem mass spectrometry (MS2) features with high similarity to library spectra, RTLS enables greater identification depth and feature reproducibility than a standard shotgun MS2 approach in low-input and single-cell samples. The platform permitted 660 single PBMCs to be measured per day, with an average of 750 protein identifications per cell and 1,648 proteins in total, achieving the necessary throughput and depth to characterize immune cell populations. Application of this scProteomic method and a new cell typing informatics approach to 2,130 PBMCs enabled the identification of both major and low-frequency cell types (∼1-2%), as well as associated proteomic markers.
Year:
2026
Clinical information of patients in scRNA-seq discovery cohort, flow cytometry validation cohort and proteomics validation cohort, including age, gender, race, ISS stage, time to disease progression (TTPD). Disease stage for WashU cohort 1.
Year:
2025
Novelty description of candidate tumor markers. Each gene is ranked according to existing literature and/or clinical trials investigating its role in multiple myeloma. Representative studies are listed.
Year:
2025
NetMHC analysis output for tissue-specific intracellular genes. Only peptides identified as strong binders (% rank
Year:
2025
Multiple myeloma (MM) is a highly refractory hematologic cancer. Targeted immunotherapy has shown promise in MM but remains hindered by the challenge of identifying specific yet broadly representative tumor markers. We analyzed 53 bone marrow (BM) aspirates from 41 MM patients using an unbiased, high-throughput pipeline for therapeutic target discovery via single-cell transcriptomic profiling, yielding 38 MM marker genes encoding cell-surface proteins and 15 encoding intracellular proteins. Of these, 20 candidate genes were highlighted that are not yet under clinical study, 11 of which were previously uncharacterized as therapeutic targets. The findings were cross-validated using bulk RNA sequencing, flow cytometry, and proteomic mass spectrometry of MM cell lines and patient BM, demonstrating high overall concordance across data types. Independent discovery using bulk RNA sequencing reiterated top candidates, further affirming the ability of single-cell transcriptomics to accurately capture marker expression despite limitations in sample size or sequencing depth. Target dynamics and heterogeneity were further examined using both transcriptomic and immuno-imaging methods. In summary, this study presents a robust and broadly applicable strategy for identifying tumor markers to better inform the development of targeted cancer therapy. Significance: Single-cell transcriptomic profiling and multiomic cross-validation to uncover therapeutic targets identifies 38 myeloma marker genes, including 11 transcribing surface proteins with previously uncharacterized potential for targeted antitumor therapy.
Year:
2025
Clinical information of patients in scRNA-seq discovery cohort, flow cytometry validation cohort and proteomics validation cohort, including age, gender, race, ISS stage, time to disease progression (TTPD). Disease stage for WashU cohort 1.
Year:
2024
Multiple myeloma (MM) is a highly refractory hematological cancer. Targeted immunotherapy has shown promise in MM but remains hindered by the challenge of identifying specific yet broadly representative tumor markers. We analyzed 53 bone marrow (BM) aspirates from 41 MM patients using an unbiased, high-throughput pipeline for therapeutic target discovery via single cell transcriptomic profiling, yielding 38 MM marker genes encoding cell-surface proteins and 15 encoding intracellular proteins. Of these, 20 candidate genes were highlighted that are not yet under clinical study, 11 of which are previously uncharacterized as therapeutic targets. The findings were cross-validated using bulk RNA-sequencing, flow cytometry, and proteomic mass spectrometry of MM cell lines and patient BM, demonstrating high overall concordance across data types. Independent discovery using bulk RNA-sequencing reiterated top candidates, further affirming the ability of single cell transcriptomics to accurately capture marker expression despite limitations in sample size or sequencing depth. Target dynamics and heterogeneity were further examined using both transcriptomic and immuno-imaging methods. In summary, this study presents a robust and broadly applicable strategy for identifying tumor markers to better inform the development of targeted cancer therapy.
Year:
2024
Novelty description of candidate tumor markers. Each gene is ranked according to existing literature and/or clinical trials investigating its role in multiple myeloma. Representative studies are listed.
Year:
2024
Novelty description of candidate tumor markers. Each gene is ranked according to existing literature and/or clinical trials investigating its role in multiple myeloma. Representative studies are listed.
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Collaborators (27)
Xueyun Zheng
Scientist
Pacific Northwest National Laboratory
Feng Chen
Professor
Washington University in St. Louis
Fengchao Yu
University of Michigan
James Fulcher
Staff Scientist
Pacific Northwest National Laboratory
David Degnan
Assistant Teaching Professor
University of Oregon
Vladislav Petyuk
scientist
Pacific Northwest National Laboratory
Song Cao
Assistant Professor
Washington University in St. Louis
Geremy Clair
Scientist
Pacific Northwest National Laboratory
Mowei Zhou
Qiushi Scholar for Experiments
Zhejiang University
Ryan Kelly
Associate Professor
Brigham Young University
Mark Fiala
Assistant Professor
Washington University School of Medicine
Wei-Jun Qian
Staff Scientist
Pacific Northwest National Laboratory
John F. DiPersio
Director, Center for Gene and Cellular Immunotherapy
Washington University in St. Louis
Scott Goldsmith
Assistant Professor
City Of Hope National Medical Center
Micah Donor
Assistant Professor
George Fox University
Dylan Ross
Data Scientist
Pacific Northwest National Laboratory
Martha Campbell-Thompson
Professor
University of Florida
Tao Liu
Sr. Staff Scientist
Pacific Northwest National Laboratory
Ravi Vij
Washington University School of Medicine
Chia-Feng Tsai
Scorpion Therapeutics (United States)
Clayton Mathews
Professor
University of Florida
Leah Gehrs
The University of Alabama
Li Ding
Associate Professor
Washington University in Saint Louis School of Medicine
Ernesto Nakayasu
Scientist
Pacific Northwest National Laboratory
Yehia Ibrahim
Scientist
Pacific Northwest National Laboratory
Michael Rettig
Washington University in St. Louis
Alexey Nesvizhskii
Professor
University of Michigan
Make your next move.
Prepare your application
Review drafts before you send them.